Worth reading
69In focus
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
80.2
Year-on-year decline in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPNet Sales11,565¥ millionYear on year +15.6%Progress 53.5%
Operating profit400¥ millionYear on year -80.2%Progress 25.4%
Ordinary income432¥ millionYear on year -78.6%Progress 27.7%
Net income attributable to owners of the parent275¥ millionYear on year -80.5%Progress 23.1%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥15.89
Operating Margin3.5%
Financial position at period-end
Total assets10,255¥ million
of which net assets 6,898 ¥ millionEquity ratio 61.6%vs. prior year-end -15.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+53
Investment-809
Financials+199
Net change-557
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥5,317 million
Segment revenueMedical Platform Business ¥5,034,669 thousand (YoY -19.7%), Smart Clinic Business ¥3,354,787 thousand (YoY +5.7%), Dental Distribution Business ¥2,391,401 thousand, DX Business ¥311,686 thousand, Other ¥480,630 thousand
Segment profitMedical Platform Business ¥1,784,678 thousand (YoY -43.2%), Smart Clinic Business ¥553,376 thousand (YoY -4.4%), Dental Distribution Business ¥-140,514 thousand, DX Business ¥85,144 thousand, Other ¥99,088 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥21,604 million (YoY +86.8%)
Operating profit¥1,573 million (YoY +293.0%)
Ordinary income¥1,557 million (YoY +260.1%)
Net income¥1,190 million (YoY +332.5%)
Annual Dividend Forecast¥30 → ¥30（0.0%）
Payout ratioFiscal year ending March 2026 188.7 % / Forecast for the fiscal year ending March 2027 43.6 %
Factors Behind Changes in Business Performance
Medical DOC's medical articles and sponsored articles were well received, and contracts for NOMOCa AI chat and NOMOCa AI call progressed in the Smart Clinic Business. The company launched the Dental Distribution Business and DX Business after making 株式会社ASANO a subsidiary, while resuming transactions with major business partners took time.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 1 / Company name 株式会社ASANO / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsThe company acquired all equity interests in 有限会社アカサカ歯材社 on 21 April 2026 and made it a consolidated subsidiary. The purchase consideration was ¥600,000 thousand. In addition, the company borrowed ¥600,000 thousand to fund the acquisition of shares and absorbed 株式会社GENOVA DESiGN effective 1 April 2026. Furthermore, stock acquisition rights lapsed following the resignation of a director, and a gain on reversal of stock acquisition rights of ¥497,319 thousand is expected to be recognized in the first quarter of the fiscal year ending March 2027.
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥3,686 thousand, Damages received ¥74,160 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥2,624 thousand
Depreciation and amortization¥85,090 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional and individual investors
Issued Shares at Period-End17,837,600
Treasury Shares at Period-End500,068
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥11,565 million (YoY +15.6%) |
| Operating profit | ¥400 million (YoY -80.2%) |
| Ordinary income | ¥432 million (YoY -78.6%) |
| Profit attributable to owners of the parent | ¥275 million (YoY -80.5%) |
| Net income per share | ¥15.89 |
| Operating Margin | 3.5% |
| Equity ratio | End of the current fiscal period 61.6% / End of previous period 76.9% |
| Total assets | ¥10,255 million |
| Net assets | ¥6,898 million |
| Cash flows from operating activities | ¥53 million |
| Cash flows from investing activities | ¥-809 million |
| Cash flows from financing activities | ¥199 million |
| Cash and cash equivalents at end of period | ¥5,317 million |
| Full-year earnings forecast | Net Sales ¥21,604 million (YoY +86.8%) / Operating profit ¥1,573 million (YoY +293.0%) / Ordinary income ¥1,557 million (YoY +260.1%) / Net income ¥1,190 million (YoY +332.5%) |
| Annual Dividend Forecast | ¥30 → ¥30（0.0%） |
| Payout ratio | Fiscal year ending March 2026 188.7 % / Forecast for the fiscal year ending March 2027 43.6 % |
| Segment revenue | Medical Platform Business ¥5,034,669 thousand (YoY -19.7%), Smart Clinic Business ¥3,354,787 thousand (YoY +5.7%), Dental Distribution Business ¥2,391,401 thousand, DX Business ¥311,686 thousand, Other ¥480,630 thousand |
| Segment profit | Medical Platform Business ¥1,784,678 thousand (YoY -43.2%), Smart Clinic Business ¥553,376 thousand (YoY -4.4%), Dental Distribution Business ¥-140,514 thousand, DX Business ¥85,144 thousand, Other ¥99,088 thousand |
| Depreciation and amortization | ¥85,090 thousand |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥3,686 thousand, Damages received ¥74,160 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥2,624 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 株式会社ASANO / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | The company acquired all equity interests in 有限会社アカサカ歯材社 on 21 April 2026 and made it a consolidated subsidiary. The purchase consideration was ¥600,000 thousand. In addition, the company borrowed ¥600,000 thousand to fund the acquisition of shares and absorbed 株式会社GENOVA DESiGN effective 1 April 2026. Furthermore, stock acquisition rights lapsed following the resignation of a director, and a gain on reversal of stock acquisition rights of ¥497,319 thousand is expected to be recognized in the first quarter of the fiscal year ending March 2027. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional and individual investors |
| Issued Shares at Period-End | 17,837,600 |
| Treasury Shares at Period-End | 500,068 |
| Factors Behind Changes in Business Performance | Medical DOC's medical articles and sponsored articles were well received, and contracts for NOMOCa AI chat and NOMOCa AI call progressed in the Smart Clinic Business. The company launched the Dental Distribution Business and DX Business after making 株式会社ASANO a subsidiary, while resuming transactions with major business partners took time. |
Items this document does not state (4)
Revision to Earnings ForecastShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Medical Platform Business, medical articles and sponsored articles were well received, while adoption of NOMOCa AI chat and AI call progressed in the Smart Clinic Business. Meanwhile, the consolidation of 株式会社ASANO marked the start of the Dental Distribution Business and DX Business, but resuming transactions with major business partners took time. For the following fiscal year, the company cited the full-year contribution from ASANO, the consolidation of 有限会社アカサカ歯材社, and the expansion of the Dental Distribution Business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.